CytoImmune CEO breaks down her 3 'pillars' of success; Former Novartis, Gilead exec Alessandro Riva to lead an ultra low-profile cell therapy outfit
Christina Coughlin loves cell therapy — pretty much defining her career since her postdoc days with Carl June in Pennsylvania.
Now as the new head honcho at CytoImmune as of Wednesday, the first-time CEO gets to work with a new type of cell therapy — CAR-NK cells, licensed from long-time NK cell researcher Michael Caligiuri and Jianhua Yu at the City of Hope National Medical Center.
And Yu is the sole member of CytoImmune’s scientific advisory board.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.